Peripheral Stent Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Peripheral Stent Market Trends and Insights

Growing Burden of PAD and Aging Population

PAD procedure volumes climbed from 933 in 2023 to 1,422 in 2024 across major systems, underscoring a widening patient pool. Prevalence touches 20% among people over 70, creating a durable base for intervention. Smoking and hypertension remain core risk factors, together accounting for nearly 70% of disease burden. Developed regions show the highest prevalence, but emerging markets such as South Korea recorded incidence growth from 2.68 to 3.09 per 1,000 persons between 2023 and 2024 as diagnostic reach improves. These demographic realities assure sustained demand for interventions and keep the peripheral stents market moving upward.

Rapid Adoption of Drug-Eluting & Bio-Resorbable Platforms

Drug-eluting devices already hold majority share, while bio-resorbable scaffolds log double-digit growth as new evidence accumulates. FDA clearance of Abbott’s Esprit BTK system in 2024 delivered the first below-the-knee dissolving stent in the United States and reduced restenosis 25.8% versus balloon angioplasty. Registry data for magnesium scaffolds showed 4.3% target lesion failure at 12 months, fuelling clinical confidence. The shift supports the broader “leave nothing behind” strategy, pushing the peripheral stents market toward next-generation solutions.^{[2]EuroIntervention, “Safety and performance of a resorbable magnesium scaffold under real-world conditions: 12-month outcomes of the first 400 patients enrolled in the BIOSOLVE-IV registry,” eurointervention.pcronline.com}

Shift to Minimally-Invasive Day-Care Procedures

ASC revenues are projected to reach USD 59 billion by 2028 as vascular cases exit inpatient settings. Same-day discharge and lower infection risk appeal to patients, while payers reward cost efficiency. Radial-to-peripheral access kits and streamlined stent delivery systems enable shorter case times, aligning with value-based purchasing. These efficiencies incentivize providers to select platforms that quicken turnover, adding momentum to the peripheral stents market.

AI-Guided Image-Based Sizing & Placement Optimisation

AI tools now deliver vessel measurements that mirror ultrasound accuracy while trimming procedure time. Trials such as FLAVOUR II confirmed comparable safety with fewer catheter exchanges, and deep-learning plaque analytics accelerate pre-procedure planning. Predictive sizing increases patency and limits reintervention, improving long-term economics of stent therapy. As hospitals adopt these systems, device makers offering AI-ready stents gain a competitive edge.

Lengthy Regulatory Pathways for Novel Materials

The FDA’s Quality Management System Regulation overhaul effective February 2026 adds process layers for magnesium and polymer platforms, prolonging time-to-market. De Novo submissions face demanding evidence rules that favor incumbents familiar with compliance. These hurdles can slow innovation diffusion and dampen growth in the peripheral stents market FDA.^{[3]Center for Devices and Radiological Health, “Quality Management System Regulation: Final Rule Amending the Quality System Regulation – Frequently Asked Questions,” FDA, fda.gov}

Price Erosion From Group Purchasing Organisations

GPOs steer more than USD 300 billion in annual purchasing, pressing device prices while collecting supplier fees. Novel stents struggle to secure premium reimbursement, and cost-focused tenders pressure margins despite clinical advantages. Developers must balance R&D spending with aggressive price points, a dynamic that can hinder adoption rates in the peripheral stents market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Bio-Resorbable Platforms Drive Innovation Despite DES Dominance

Drug-eluting stents retained 51.66% of 2025 revenue and are forecast to advance steadily as clinical familiarity persists. The peripheral stents market size for drug-eluting platforms is projected to rise in line with the overall 7.24% CAGR, supported by ongoing design refinements that boost patency. Bio-resorbable scaffolds, while only a fraction of sales today, are tracking 10.05% CAGR, the fastest within the product mix, thanks to FDA endorsements that validate safety and efficacy. Covered and bare-metal devices meet niche needs but face share migration toward higher-performing alternatives.

Physicians cite the Eluvia system’s one-year patency record and the Esprit BTK scaffold’s dissolving profile as evidence that new chemistry and coatings can outperform legacy metal frames. Growing clinical confidence, combined with reimbursement alignment for innovative therapies, fuels capital budgets aimed at next-generation products. As data matures, the peripheral stents market is likely to rebalance toward platforms that combine proven drug delivery with resorption to minimize long-term complications.

By Artery Type: Infrapopliteal Segment Gains Momentum as BTK Treatments Advance

Femoral-popliteal interventions generated 35.88% of 2025 revenue, underscoring their central role in PAD management. That dominance rests on a large installed base of equipment and clinical protocols perfected over decades. Yet infrapopliteal procedures are tipped for 9.32% CAGR, eclipsing all other artery categories. The introduction of purpose-built below-the-knee scaffolds, improved imaging, and rising chronic limb-threatening ischemia awareness underpin that growth. Iliac, renal, and carotid segments maintain steady demand, but incremental gains remain modest relative to infrapopliteal momentum.

Infrapopliteal devices benefit from unmet clinical need, as earlier interventions extend limb salvage and improve quality of life. Successful early outcomes from dissolving platforms are expected to widen physician adoption. That shift will expand the peripheral stents market share devoted to distal limb revascularization, especially as clinical guidelines endorse earlier BTK treatment.

By Material: Polymer Innovation Challenges Nitinol Supremacy

Nitinol accounted for 64.02% of 2025 revenue, reflecting its unmatched shape-memory properties that support self-expanding behavior. Supply chain strain and fabrication costs, however, are prompting exploration of alternative materials. Polymer and composite scaffolds are growing 8.12% annually, and cobalt-chromium maintains a foothold in balloon-expandable use cases. Stainless steel remains relevant largely in cost-sensitive markets or specific clinical scenarios.

Bio-resorbable polymers such as PLLA and magnesium composites demonstrate high degradation predictability and respectable radial strength. Registries indicate near-complete absorption by two years, a feature valued by clinicians looking to avoid late-stage complications. The peripheral stents market size allocated to polymer solutions is expected to increase as safety data and volume manufacturing lower per-unit costs.

By Deployment Mechanism: Self-Expanding Systems Leverage Nitinol Advantages

Self-expanding devices held 68.21% of revenue in 2025, leveraging nitinol’s elasticity to accommodate vessel motion and chronic outward force. These attributes limit restenosis and fracture risk in tapered or mobile arteries, translating into lower retreatment rates. Balloon-expandable systems, growing at 7.86% CAGR, gain share in calcified or ostial lesions requiring precise placement and immediate high radial force.

Recent delivery-system improvements streamline balloon-expandable deployment, making them more competitive in complex anatomies. Continual refinements in catheter profiles and fluoroscopic markers will sustain unit growth. Still, long-term dominance of self-expanding platforms appears secure, anchoring a large portion of the peripheral stents market.

By End User: ASC Growth Reshapes Procedural Economics

Hospitals retained 64.85% of global revenue in 2025 as tertiary centers handled the highest-acuity cases and maintained extensive imaging suites. Nonetheless, ASCs, projected for 8.54% CAGR, are gradually absorbing routine and mid-complexity procedures. Same-day discharge, lower overhead, and favorable patient satisfaction scores bolster the ASC value proposition.

Device developers now design packaging and inventory models tailored to outpatient environments. Integrated kits reduce setup time, and single-use delivery systems minimize reprocessing steps. As reimbursement incentives align with site-neutral payment agendas, ASCs are likely to account for a bigger slice of the peripheral stents market.

Geography Analysis

North America generated 38.55% of 2025 revenue, with the United States representing the largest single market due to well-funded health systems, routine screening, and broad reimbursement for endovascular care. Canada and Mexico contribute incrementally as access widens, though reimbursement and regulatory nuances shape product mix. Successful large-scale adoption of drug-eluting and bio-resorbable solutions solidifies regional leadership.

Europe follows closely, propelled by harmonized clinical guidelines and a single-market regulatory environment that speeds cross-border adoption. The European Society for Vascular Surgery emphasizes individualized care and endorses drug-eluting systems, supporting the peripheral stents market across member states. Western European countries benefit from established value-based care frameworks, and Central & Eastern Europe show emerging growth as infrastructure modernizes.

Asia-Pacific is the fastest climber, advancing at a 8.90% CAGR through 2031. China’s target-lesion failure dropped from 6.8% to 4.3% between 2023 and 2024 as advanced stents penetrated tier-one cities. India, aided by updated Medical Device Rules, recorded peripheral interventions rising from 2,850 in 2023 to 3,420 in 2024. South Korea and Japan remain technology-forward, quickly incorporating AI imaging and next-generation materials. Improved payor coverage and government focus on cardiovascular disease drive capacity expansion, lifting the peripheral stents market.

Latin America and the Middle East & Africa present untapped opportunity. Reimbursement variability and budget constraints slow uptake, but epidemiological transition and public-health campaigns create long-term upside. Pilot projects with cost-sharing models may establish proof-points that unlock broader adoption. As training partnerships and mobile cath-labs proliferate, regional stakeholders anticipate gradual but steady contribution to global volumes.

Regulatory Landscape

Peripheral stents, particularly drug-eluting platforms, sit within high-scrutiny regulatory pathways as implantable, device-drug combination products. In the United States, peripheral drug-eluting stents are regulated by FDA CDRH as Class III combination products and typically require Premarket Approval (PMA), with FDA combination-product jurisdiction governed by the Primary Mode of Action determination and cross-center interaction when drug data are integral to the submission. A major compliance inflection point is the FDA Quality Management System Regulation (QMSR) that takes effect on February 2, 2026, integrating ISO 13485:2016 expectations into device quality systems, while additional FDA combination-product guidance activity in 2025 (including UDI-focused draft guidance for combination products) increases documentation and traceability requirements for manufacturers.

In Europe, the EU Medical Device Regulation (MDR) (EU) 2017/745 remains the core framework for peripheral stents as implantable devices, reinforcing clinical evaluation, post-market surveillance, and, where applicable, post-market clinical follow-up obligations. Commission Delegated Regulation (EU) 2026/1451 (adopted March 20, 2026) updated the list of implantable devices exempted from mandatory clinical investigations, but it does not remove the need to maintain robust clinical evaluation documentation under MDR. Across regions, internationally recognized standards such as ISO 12417-1:2024 for vascular device-drug combination products increasingly anchor technical documentation and test expectations for drug-eluting peripheral stents.

Value Chain Analysis

The peripheral stent value chain begins with upstream specialty raw materials and component manufacturing, most notably nitinol and other fatigue-sensitive alloys for self-expanding frames, polymers/coatings for drug-eluting and bio-resorbable platforms, and catheter-based delivery components that must meet tight dimensional tolerances. Supplier capability and consistency are strategic differentiators, with the PRIME (PRoficient Ingot Material Evaluation) project launched in July 2025 by Fort Wayne Metals, Vascotube, EUROFLEX, ADMEDES, and MeKo MedTech to standardize nitinol material consistency and support yield, performance, and regulatory documentation for stents and related components.

Midstream, OEMs integrate laser-cut or braided scaffolds with drug-polymer coatings, sterilization, packaging, and quality systems aligned to evolving compliance requirements (including FDA QMSR from February 2026 for the US). Downstream, distribution is shaped by large hospital systems and outpatient care expansion, with companies using exclusive distribution agreements to broaden procedural tool access and embed into physician workflows. For example, Medtronic expanded its US commercialization toolkit via exclusive distribution arrangements for specialized peripheral access tools (Future Medical Design peripheral guidewires, announced July 2025) and broader neurovascular portfolios (Contego Medical). Adjacent clinical collaborations also influence future product availability and evidence generation, such as the September 2025 Bentley and Terumo Aortic partnership planning an FDA IDE submission in the first half of 2026 for a combined system study.

Market Opportunities and Future Outlook

A key opportunity area is technology differentiation in drug-eluting and resorbable solutions that reduce device count per procedure and expand treatment options in below-the-knee disease. In July 2026, Abbott received US FDA approval for a longer-length (76 mm) Esprit BTK everolimus-eluting resorbable scaffold, underscoring demand for designs that improve procedural efficiency in chronic limb-threatening ischemia (CLTI) by addressing longer lesion segments with fewer implants. Regulatory acceleration programs also create whitespace for faster market entry of new peripheral drug-eluting stent systems; in May 2026, MicroPort Endovastec received NMPA Green Channel designation in China for its SunFlow drug-eluting peripheral stent system, highlighting an active route for innovative devices to advance in high-growth settings.

Product and evidence strategies are also evolving around antiproliferative drug choice and lesion-specific performance, enabling portfolio breadth across drug-eluting, covered, and combination technologies used in restenosis and complex lesion management. Europe remains a competitive proving ground under MDR where CE Mark achievements can translate into broader tenders and clinical adoption; for instance, Becton, Dickinson and Company received CE Mark approval in March 2026 for the Revello vascular covered stent for iliac artery disease, adding competitive pressure in the covered-stent segment. Alongside these developments, continued attention to long-term outcomes and post-market evidence underpins purchasing decisions across hospitals and ambulatory surgical centers, rewarding manufacturers that pair novel platforms with scalable quality systems and data generation.